1. Home
  2. MQ vs GENB Comparison

MQ vs GENB Comparison

Compare MQ & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Marqeta Inc.

MQ

Marqeta Inc.

HOLD

Current Price

$4.43

Market Cap

1.8B

Sector

Technology

ML Signal

HOLD

GENB

Generate Biomedicines Inc. Common Stock

N/A

Current Price

$12.46

Market Cap

1.7B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
MQ
GENB
Founded
2010
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.7B
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
MQ
GENB
Price
$4.43
$12.46
Analyst Decision
Hold
Strong Buy
Analyst Count
10
6
Target Price
$5.36
$23.20
AVG Volume (30 Days)
2.6M
314.2K
Earning Date
05-05-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$624,884,000.00
N/A
Revenue This Year
$16.89
N/A
Revenue Next Year
$16.36
$16.58
P/E Ratio
N/A
N/A
Revenue Growth
23.25
N/A
52 Week Low
$3.70
$11.00
52 Week High
$7.04
$14.21

Technical Indicators

Market Signals
Indicator
MQ
GENB
Relative Strength Index (RSI) 61.13 50.07
Support Level $4.37 $11.39
Resistance Level $4.50 $13.40
Average True Range (ATR) 0.14 0.73
MACD 0.02 0.00
Stochastic Oscillator 84.62 57.87

Price Performance

Historical Comparison
MQ
GENB

About MQ Marqeta Inc.

Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.

About GENB Generate Biomedicines Inc. Common Stock

Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.

Share on Social Networks: